<p>Motley Fool's Michael Douglass and Todd Campbell shed light on how Celgene's deal-making frenzy positions it as a potential MS leader and offer up insight into how to value immuno-oncology stocks.</p>

Motley Fool's Michael Douglass and Todd Campbell shed light on how Celgene's deal-making frenzy positions it as a potential MS leader and offer up insight into how to value immuno-oncology stocks.

<p>Motley Fool's Michael Douglass and Todd Campbell shed&nbsp;light on how&nbsp;Celgene's deal-making frenzy positions it as a potential MS leader&nbsp;and offer up insight into how to value&nbsp;immuno-oncology stocks.</p>

Healthcare: Celgene's Deal – Happy Management Does It Again

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Celgene's Deal – Happy Management Does It Again

Sign up to save your podcasts

Healthcare: Celgene's Deal – Happy Management Does It Again

Healthcare: Celgene's Deal – Happy Management Does It Again